Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
03:14p NISSAN MOTOR : Japan auto-makers commit $50m to hydrogen stations
03:14p FINDINGS FROM UNIVERSITY OF BASQUE COUNTRY BROADEN UNDERSTANDING OF FUNGAL ECOLOGY (TAXONOMIC GAP IN WOOD-INHABITING FUNGI : identifying understudied...
03:14p FUJITSU : announces new high end storage systems
03:14p Patent Issued for Semiconductor Laser Element
03:14p NVIDIA : Patent Application Titled "Logic Circuitry Configurable to Perform 32-Bit Or Dual 16-Bit Floating-Point Operations" Published Online
03:13p EL CAPITAN PRECIOUS METALS : Renegotiates Contract Terms to Secure Higher Price Per Ton from Chinese Buyer
03:13p Hasbro's Trademark Application for "N-STRIKE DISK SHOT" Filed
03:12p OppenheimerFunds Completes RIA Team
03:12p FANUC : Patent Issued for Control System Equipped with Detachable Control Panel
03:12p WPP : Ogilvy CommonHealth Worldwide :'s Sebastien Boisseau Invited to Present at the Medico-Legal Conference
Latest news
Advertisement
Hot News 
ACIO HLDG : Federal judge enters permanent injunction against Acino Products, LLC
SPEEDY HIRE : Dealt Triple Blow As Results To Miss Expectations (REPEAT)
BETTER CAPITAL PCC : Reports Contrasting Results For 2009 And 2012 Cells
GRAHAM : Completes Spin-off of Cable ONE
MISSION MARKETING : /the mission launches Mongoose
Most Read News
08:29a ROYAL DUTCH SHELL A : Makes Investment Decision On Appomattox Project
06/30 PENTAIR : shares jump on news that Trian Fund has targeted stock
11:30a ACE buys upmarket Chubb in biggest ever insurance takeover
06/30DJBrookfield Approaches Australia's Asciano With $6.8 Billion Offer
06/30DJWILLIS-TOWERS WATSON : A Merger of Equals--Not Exactly
Most recommended articles
03:06p U.S. sues to stop Electrolux's purchase of GE's appliance business
02:59p DONALD TRUMP : Macy's becomes latest to cut ties with Donald Trump
02:54pDJNo Grounds for Further Talks on Greece, Says Eurogroup Head Dijsselbloem
02:53p ECB says emergency funding for Greek banks held steady
02:49p U.S. probing whether airlines collude to keep airfares high